Searched for
CONTRACEPTIVE DRUGMAKER
Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Sun Pharma clarifies $10 bn Organon acquisition report, calls it 'speculative in nature'Sun Pharma has addressed speculation regarding a potential $10 billion acquisition of US firm Organon. The Indian drugmaker stated the repo...
- Glenmark recalls product in US over manufacturing issue: USFDAGlenmark Pharmaceuticals is taking proactive measures by recalling over 26,000 packs of birth control pills in the US. Citing issues with i...
- India’s cheap birth control pills in US could vanish under Trump’s 250% tariff threatDonald Trump's tariff threat jeopardizes affordable Indian medicines in the US. Birth control pills, hypertension, and depression treatment...
- Mylan may buy contraceptive co Famy Care for Rs 3,000 croreMylan is said to have pipped private equity bids from Bain Capital and Advent to move closer to a deal. Hong Kong-based AIF Capital holds 1...
- Ranbaxy rallies over 3% intraday as FDA approves Gurgaon & Romania R&D centresUnits of Ranbaxy's R&D centre at Gurgaon and its clinical research centre at Terapia Ranbaxy, its subsidiary in Romania, were cleared by US...
- Good news trickles in for Ranbaxy, FDA approves Gurgaon & Romania R&D centresSun will acquire Ranbaxy in an all-share deal that will give it a 56% stake in the combined entity while Daiichi Sankyo will have 9% holdin...
- Glenmark Pharma rallies over 3% on talks to sell oral contraceptive unit"Given complex manufacturing processes and high investments, the competition is low in the segment and typically attracts only a few player...
- Ten stocks in focus in Thursday morning tradeIndian markets are likely to trade in a range. Here is a list of ten stocks which are likely to be in focus in trade today.
- Glenmark in talks to sell oral contraceptive unitThe company promoted by Glenn Saldanha has begun talks with some of the leading local and global drugmakers.
- Lupin: US & Japan strong show adds shine to company's showA strong show in two key markets, US and Japan, helped boost the performance of drugmaker Lupin, one of the most consistent performers in t...
- Cipla looking to expand contraceptive pills business; in talks with International Planned ParenthoodThe country's second-largest pharmaceuticals company, Cipla, is in talks with an international health group to expand its contraceptive pil...
- Pfizer recalls 1 million contraceptive medicine packsPfizer recalled 1 mn birth-control packs after discovering that pills were mixed up inside the packages, possibly putting women at risk.
- Lupin gains on USFDA nod; Goldman recommends 'Buy'Shares of drugmaker Lupin rose nearly 2 percent after it received the US regulatory approval on Tuesday to launch oral contraceptive
- Piramal told to stop drug advt in guise of awarenessDrugmakers promoting their brands through awareness campaigns have not gone down well with the country's drug regulator, who had banned suc...
- Baring may acquire 15% in Famy CareBaring Private Equity Partners (India) is the front-runner to buy about 15% stake in Mumbai-based drugmaker Famy Care for around $40 millio...
- Lupin can't sell pill in US, Teva files patent suitIsraeli drugmaker Teva Pharma has filed a patent infringement suit in the US against Lupin that prevents the Indian pharma company from sel...
- US FDA inspects Lupin's new plant in IndoreThe US drug regulator has started inspection of Indian drugmaker Lupin’s upcoming plant at Indore last week, a person close to the developm...
- Teva to buy Barr Pharma for $7.5 bnIn the latest drug consolidation, Teva Pharmaceutical said on Friday it will buy rival generic drugmaker Barr Pharmaceuticals for nearly $7...
Load More
